

Resource Summary Report

Generated by [NIF](#) on Sep 2, 2026

Search Orphan Drug Designations and Approvals

RRID:SCR_010256

Type: Tool

Proper Citation

Search Orphan Drug Designations and Approvals (RRID:SCR_010256)

Resource Information

URL: <http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm>

Proper Citation: Search Orphan Drug Designations and Approvals (RRID:SCR_010256)

Description: Database of Orphan Drug Product designations. Searches may be run by entering the product name, orphan designation, and dates. Results can be displayed as a condensed list, detailed list, or an Excel spreadsheet.

Resource Type: data or information resource, database

Resource Name: Search Orphan Drug Designations and Approvals

Resource ID: SCR_010256

Alternate IDs: nlx_156908

Record Creation Time: 20220129T080257+0000

Record Last Update: 20260829T183004+0000

Ratings and Alerts

No rating or validation information has been found for Search Orphan Drug Designations and Approvals.

No alerts have been found for Search Orphan Drug Designations and Approvals.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Mo Q, et al. (2025) Drug lag and associated factors of orphan drugs approved by the U.S. in China. *Frontiers in pharmacology*, 16, 1595497.

Lee J, et al. (2023) COVID-19 drugs: potential interaction with ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein. *Journal of pharmaceutical investigation*, 53(2), 191.

Mechler K, et al. (2020) Disease awareness or subtle product placement? Orphan diseases featured in the television series "House, M.D." - a cross-sectional analysis. *BMC medical ethics*, 21(1), 20.

Boccanegra B, et al. (2020) Safety issues and harmful pharmacological interactions of nutritional supplements in Duchenne muscular dystrophy: considerations for Standard of Care and emerging virus outbreaks. *Pharmacological research*, 158, 104917.

Jaros??awski S, et al. (2017) Quantifying the persisting orphan-drug shortage public health crisis in the United States. *Journal of market access & health policy*, 5(1), 1269473.

Gibson S, et al. (2015) Orphan drug incentives in the pharmacogenomic context: policy responses in the US and Canada. *Journal of law and the biosciences*, 2(2), 263.